Tarle M
Nuclear Medicine and Oncology Clinic, Clinical Hospital, Dr. M. Stojanovic, Croatia, Yugoslavia.
Anticancer Res. 1988 Jul-Aug;8(4):569-72.
Serum PAP, PSA, and testosterone values were measured in 101 men with prostatic nodule. In 71 patients prostatic cancer was detected and in 62 of those patients monitoring studies of the same parameters were assessed on 153 sera by applying a radioimmunodetective procedure. The PSA test, when compared to PAP values, offers significantly greater sensitivity towards small tumor burdens in early stages of the disease, and enables, in some cases, the prediction of tumor recurrence before clinical symptoms have been manifested. The results of this study indicate that the addition of the PSA assessment to the standard protocol of prostate cancer diagnosis and treatment, either alone or together with PAP in a double-marker assay, is promising for more accurate staging and monitoring of patients with prostatic tumors.
对101例有前列腺结节的男性进行了血清酸性磷酸酶（PAP）、前列腺特异性抗原（PSA）和睾酮值的检测。在71例患者中检测到前列腺癌，其中62例患者通过放射免疫检测法对153份血清的相同参数进行了监测研究。与PAP值相比，PSA检测对疾病早期小肿瘤负荷的敏感性显著更高，并且在某些情况下能够在临床症状出现之前预测肿瘤复发。本研究结果表明，在前列腺癌诊断和治疗的标准方案中增加PSA评估，无论是单独使用还是与PAP一起进行双标记检测，对于更准确地分期和监测前列腺肿瘤患者都很有前景。
